Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bc2922b791dbd5089c2ee3958100e6156> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bc2922b791dbd5089c2ee3958100e6156 NCIT_P378 "NCI" @default.
- Bc2922b791dbd5089c2ee3958100e6156 type Axiom @default.
- Bc2922b791dbd5089c2ee3958100e6156 annotatedProperty IAO_0000115 @default.
- Bc2922b791dbd5089c2ee3958100e6156 annotatedSource NCIT_C185598 @default.
- Bc2922b791dbd5089c2ee3958100e6156 annotatedTarget "A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) mesothelin (MSLN) and simultaneously produce interleukin-7 (IL-7) and C-C motif chemokine 19 (CCL19), with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion and reintroduction into the patient, the autologous anti-MSLN CAR-T cells TAK-103 specifically target and kill MSLN-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types. IL-7 promotes the proliferation and survival of T-cells. CCL19 enhances the migration of T-cells and dendritic cells (DCs)." @default.